Radiomics of post-treatment total body scan for prediction of successful I-131 ablation in low risk papillary thyroid carcinoma patients.

Completed

• Conditions: Radiomics, Artificial Intelligence, Thyroid cancer, Total body scan, Successful ablation; ow risk PTC patients who underwent total/near total thyroidectomy and I-131 ablation 30 mCi, without RAI-avid metastatic foci outside the thyroid bed on the post-treatment TBS

• Registration Number: TCTR20230816004
• Lead Sponsor: /A

Brief Summary

The combined model showed good performance in all metrics with accuracy, precision, F1-scores, sensitivity, and specificity of 0.74, 0.76, 0.78, 0.81, and 0.62, respectively.

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-10-01
• Study Start: 2023-08-16
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

1. Low risk PTC patients who underwent total/near total thyroidectomy and I-131 ablation 30 mCi, without RAI-avid metastatic foci outside the thyroid bed on the post treatment TBS.
2. All TBS were acquired at King Chulalongkorn Memorial Hospital (KCMH), Bangkok, Thailand, using the same protocol with matrix size of 256 X 256 and 5-minute acquisition using high energy collimator.

Exclusion Criteria

Patients with serum anti-Tg level more than 100 IU/ml (5) at pre-ablative period or during follow up, patients who were lost to follow up at 6-12 months, and patients whose I-131 TBS was unable to define region of interest (ROI) by automated segmentation.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
successful ablation at 12 months after treatment ATA guideline

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A